Honokiol

• CAT Number: I003289
• CAS Number: 35354-74-6
• Molecular Formula: C₁₈H₁₈O₂
• Molecular Weight: 266.33
• Purity: ≥95%
• Target: IκB/IKK
• Solubility: Soluble to 100 mM in DMSO and to 100 mM in ethanol
• Storage: 3 years -20C powder
• IC50: 30 uM (DBTRG-05MG cell) [1]
• InChI: InChI=1S/C18H18O2/c1-3-5-13-7-9-18(20)16(11-13)14-8-10-17(19)15(12-14)6-4-2/h3-4,7-12,19-20H,1-2,5-6H2
• InChIKey: FVYXIJYOAGAUQK-UHFFFAOYSA-N
• SMILES: C=CCC1=CC(=C(C=C1)O)C2=CC(=C(C=C2)O)CC=C

Honokiol(NSC-293100), a hydroxylated biphenyl compound isolated from the Chinese herb Magnolia officinalis, has been reported to have anticancer activities in a variety of cancer cell lines.IC50 Value: 30 uM (DBTRG-05MG cell) [1]Target: Apoptosis inducerin vitro: Honokiol was observed to reduce DBTRG-05MG cell viability in a dose-dependent manner. At a dose of 50 μM, honokiol markedly decreased the expression of Rb protein and led to the cleavage of poly(ADP-ribose) polymerase and Bcl-xL to promote apoptosis in the cancer cells. In addition, markers of autophagy, including Beclin-1 and LC3-II, were also significantly increased. In addition to apoptosis, honokiol was also able to induce autophagy in the DBTRG-05MG cells [1]. Honokiol treatment showed potent inhibitory effects on TNF-α-induced RASMC proliferation, which were associated with G0/G1 cell cycle arrest and downregulation of cell cycle-related proteins, including cyclin D1, cyclin E, cyclin-dependent kinase (CDK)2 and CDK4. Furthermore, honokiol treatment led to the release of cytochrome c into cytosol and a loss of mitochondrial membrane potential (ΔΨm), as well as a decrease in the expression of Bcl-2 and an increase in the expression of Bax. Treatment with honokiol also reduced TNF-α-induced phosphorylation of p38, extracellular signal-regulated kinase 1/2, and c-Jun N-terminal kinase [2].in vivo: Daily intraperitoneal injection of honokiol starting at postnatal day (P) 12 in an oxygen-induced retinopathy (OIR) mouse model significantly reduced retinal neovascularization at P17. Administration of honokiol also prevents the oxygen-induced central retinal vaso-obliteration, characteristic feature of the OIR model. Additionally, honokiol enhanced physiological revascularization of the retinal vascular plexuses [3]. Sprague-Dawley rats were pretreated with honokiol and exposed to a 30-min myocardial ischemia followed by 2-h coronary reperfusion. Pretreatment with honokiol significantly reduced infarct size, and serum creatine kinase (CK) and lactate dehydrogenase (LDH) release compared with those in the I/R group following a 2-h reperfusion. The malondialdehyde (MDA) level, myeloperoxidase (MPO) activity, concentrations of tumor necrosis factor (TNF)-α and interleukin (IL)-6 and expression level of NF-κB were all reduced by honokiol pretreatment, while honokiol inhibited the decreases in superoxide dismutase (SOD) and catalase (CAT) activities [4].Toxicity:

Reference

1:Transcriptomic analysis of Saccharomyces cerevisiae upon honokiol treatment. Zhu X, Zou S, Li Y, Liang Y.Res Microbiol. 2017 May 10. pii: S0923-2508(17)30089-X. doi: 10.1016/j.resmic.2017.04.007. [Epub ahead of print] PMID: 28499955 2:Therapeutic Action of Honokiol on Postoperative Ileus via Downregulation of iNOS Gene Expression. Mihara T, Mikawa S, Kaji N, Endo M, Oikawa T, Tong-Rong J, Ozaki H, Hori M.Inflammation. 2017 May 10. doi: 10.1007/s10753-017-0576-7. [Epub ahead of print] PMID: 28493080 3:Honokiol inhibits ultraviolet radiation-induced immunosuppression through inhibition of ultraviolet-induced inflammation and DNA hypermethylation in mouse skin. Prasad R, Singh T, Katiyar SK.Sci Rep. 2017 May 10;7(1):1657. doi: 10.1038/s41598-017-01774-5. PMID: 28490739 Free PMC Article4:Honokiol Alleviates Hypertrophic Scar by Targeting Transforming Growth Factor-β/Smad2/3 Signaling Pathway. Zhao D, Wang Y, Du C, Shan S, Zhang Y, Du Z, Han D.Front Pharmacol. 2017 Apr 19;8:206. doi: 10.3389/fphar.2017.00206. eCollection 2017. PMID: 28469575 Free PMC Article5:Honokiol Induces Apoptosis, G1 Arrest, and Autophagy in KRAS Mutant Lung Cancer Cells. Luo LX, Li Y, Liu ZQ, Fan XX, Duan FG, Li RZ, Yao XJ, Leung EL, Liu L.Front Pharmacol. 2017 Apr 11;8:199. doi: 10.3389/fphar.2017.00199. eCollection 2017. PMID: 28443025 Free PMC Article6:Development of a chitosan-based nanoparticle formulation for ophthalmic delivery of honokiol. Deng F, Hu W, Chen H, Tang Y, Zhang L.Curr Drug Deliv. 2017 Apr 19. doi: 10.2174/1567201814666170419113933. [Epub ahead of print] PMID: 28425869 7:Honokiol, an activator of Sirtuin-3 (SIRT3) preserves mitochondria and protects the heart from doxorubicin-induced cardiomyopathy in mice. Pillai VB, Kanwal A, Fang YH, Sharp WW, Samant S, Arbiser J, Gupta MP.Oncotarget. 2017 Mar 11. doi: 10.18632/oncotarget.16133. [Epub ahead of print] PMID: 28423723 Free Article8:Honokiol-loaded polymeric nanoparticles: an active targeting drug delivery system for the treatment of nasopharyngeal carcinoma. Yang B, Ni X, Chen L, Zhang H, Ren P, Feng Y, Chen Y, Fu S, Wu J.Drug Deliv. 2017 Nov;24(1):660-669. doi: 10.1080/10717544.2017.1303854. PMID: 28368206 9:Erratum to: Honokiol activates AMP-activated protein kinase in breast cancer cells via LKB1-dependent pathway and inhibits breast carcinogenesis. Nagalingam A, Arbiser JL, Bonner MY, Saxena NK, Sharma D.Breast Cancer Res. 2017 Mar 28;19(1):39. doi: 10.1186/s13058-017-0829-2. No abstract available. PMID: 28351375 Free PMC Article10:Biodegradable polymeric micelles coencapsulating paclitaxel and honokiol: a strategy for breast cancer therapy in vitro and in vivo. Wang N, Wang Z, Nie S, Song L, He T, Yang S, Yang X, Yi C, Wu Q, Gong C.Int J Nanomedicine. 2017 Feb 23;12:1499-1514. doi: 10.2147/IJN.S124843. eCollection 2017. PMID: 28260895 Free PMC Article